Status:
COMPLETED
SAlt Diet and Various Biomarkers Effects on Blood Pressure and Proteinuria During Inhibition of VEGF)
Lead Sponsor:
University Hospital, Tours
Conditions:
Patient Starting Bevacizumab
Cancer
Eligibility:
All Genders
18+ years
Brief Summary
Bevacizumab is an anti-angiogenic treatment used to treat various solid cancers. Previous studies have shown that this treatment may have adverse effects like hypertension and proteinuria. This is an...
Detailed Description
Participants will be invited to participate to this research study by their oncologist within 1 to 2 weeks before starting bevacizumab treatment, as part of standard treatment. They will finish the re...
Eligibility Criteria
Inclusion
- Adult patient
- With a solid cancer for which a treatment with bevacizumab (Avastin®) is indicated in accordance with its marketing authorization
Exclusion
- Renal cancer
- Recent changes in antihypertensive treatment(s) in the last month, with the exception for diuretics where treatment stability of at least 3 months will be required
- Patients who do not wish to participate to the study
Key Trial Info
Start Date :
April 26 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 15 2022
Estimated Enrollment :
26 Patients enrolled
Trial Details
Trial ID
NCT03842917
Start Date
April 26 2019
End Date
June 15 2022
Last Update
November 8 2022
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Medical Oncology Service, University Hospital, Tours
Tours, France, 37044
2
Oncological Gastroenterology Service, University Hospital, Tours
Tours, France, 37044
3
Pneumology, University Hospital, Tours
Tours, France, 37044